在喘发作管理中对系统性皮质类固醇反应的表型化 (PRISMA):观察和转化试点研究的协议
Carlos Andrés Celis-Preciado1,2, Simon Leclerc1, Martine Duval1
1Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
BMJ open respiratory research
|November 8, 2023
概括
这项试点研究探讨了血中乙氨基酸和FeNO如何预测喘恶化的治疗反应. 了解这些生物标志物可以指导个性化喘发作治疗.
科学领域:
- 肺部病理学 肺部病理学
- 临床医学 临床医学
- 翻译研究是翻译研究.
背景情况:
- 喘恶化是异质的,对像皮质类固醇和抗生素等标准治疗的反应是可变的.
- 生物标志物,如血中乙酸氨基和分数呼出的氧化 (FeNO) 在慢性喘中至关重要,但它们在急性恶化中的作用尚不清楚.
- 对喘发作需要个性化治疗策略,考虑到个体的炎症和微生物特征.
研究的目的:
- 根据2型炎症生物标志物评估急性喘时对皮质类固醇的临床和生物反应.
- 探索血液中乙酸细胞计数和FeNO在预测喘恶化治疗结果中的有用性.
- 引导开发个性化治疗策略来管理喘发作.
主要方法:
- 一项观察性纵向试点研究,涉及50名喘患者和12名健康对照.
- 多模式评估包括血液中乙蛋白 (静脉和治疗点),FeNO和呼吸道感染检测.
- 患者在基线和7天的皮质类固醇疗程后被评估,主要分析侧重于FEV1相对于2型炎症状况的变化.
主要成果:
- 这项研究旨在确定2型炎症状态 (定义为血液中乙酸盐和/或FeNO) 是否会影响喘恶化时对皮质类固醇治疗的反应.
- 关键次要分析将检查症状得分的变化以及患者中达到临床重要差异最小的比例.
- 探索性分析将调查临床,肺功能,炎症和微生物群参数之间的相关性,以及临床检测的可靠性.
结论:
- 这项试点研究将为一项更大的试验提供信息,比较基于炎症生物标志物的治疗反应.
- 预计这些发现将为喘发作的个性化皮质类固醇治疗提供有价值的指导.
- 该研究旨在通过将生物标志物数据整合到急性喘管理的临床决策中来增强治疗策略.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
01:20Asthma: Pathogenesis and Management
420
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
420
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
310
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
310